Switzerland · Delayed Price · Currency is CHF Cosmo Earnings Call Transcripts
Fiscal Year 2025
-
Structural transformation delivered, with 85% of revenue now recurring and EBITDA exceeding guidance. 2026 outlook targets double-digit recurring revenue growth, expanding AI MedTech, and a value-defining late-stage dermatology asset, supported by a strong cash position.
-
H1 2025 saw strong revenue and EBITDA growth, driven by GI Genius and Winlevi, with raised full-year guidance. Strategic focus remains on clinical pipeline advancement, AI medtech expansion, and regulatory milestones, supported by a robust cash position.
-
A new 2030 vision targets 39% annual revenue growth, driven by AI-enabled MedTech, global expansion of Winlevi, and the launch of Breezula for hair loss. Strategic focus on gut, skin, and AI, plus digital health, positions the business for high-margin, sustainable growth.
Fiscal Year 2024
-
Record 2024 revenues and profit were driven by strong growth in WINLEVI and GI Genius, with robust cash flow, zero debt, and major pipeline progress. 2025 guidance projects continued double-digit recurring revenue growth, heavy R&D investment, and a strong balance sheet.
-
Revenue surged to EUR 136.2 million in H1 2024, driven by a major Medtronic payment and strong growth in health tech and dermatology. Guidance for full-year revenue and profit was reaffirmed, with key product launches and regulatory milestones expected by year-end.